Abbott LaboratoriesvsAstraZeneca

ABT and AZN stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$104.71

Value $182B

-2.55%
ABT's page

Over the last year, with dividends, ABT moved -17.8% and AZN +3.3%. Dividend yield: ABT 2.41%, AZN none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$182B

    AZN–

  • Revenue, 12 months

    ABT$48.2B

    AZN$58.7B

    AZN is 1.2 times ABT

  • Net income, 12 months

    ABT$4.7B

    AZN$10.2B

    AZN is 2.2 times ABT

  • Operating margin

    ABT13.8%

    AZN23.4%

    9.6 points apart

  • ROIC

    ABT6.3%

    AZN14.8%

    8.5 points apart

  • P/E

    ABT38.7

    AZN–

  • Dividend yield

    ABT2.4%

    AZN0.0%

    2.4 points apart

  • 5-year return

    ABT-11.6%

    AZN+74.4%

    86.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-11.6%

AZN+74.4%

10015020020222023202420252026
Returns by period
PeriodABTWith dividendsAZNWith dividends
1 year since November 14, 2025-17.8%Price -19.8%+3.3%Price +2.3%
3 years since November 17, 2023+12.0%+3.9% a yearPrice +5.2%+49.8%+14.4% a yearPrice +42.1%
5 years since November 16, 2021-11.6%-2.4% a yearPrice -20.0%+74.4%+11.8% a yearPrice +58.1%
10 years since November 18, 2016+217.1%+12.2% a yearPrice +162.8%+341.4%+16.0% a yearPrice +236.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesAZNAstraZeneca

Valuation

ABTAZN
Valuation
Price$104.71$182.27
Market value$182B–
Enterprise value (EV)$209B–
P/E38.7–
P/E, 5-year median33.732.2
P/B3.6–
EV/EBIT31.4–
Free cash flow yield3.7%–

Results and growth

ABTAZN
Results and growth
Revenue, 12 months$48.2B$58.7B
Net income, 12 months$4.7B$10.2B
Free cash flow, 12 months$6.8B$11.8B
Earnings per share, 12 months$2.69$6.54
Revenue growth, year on year5.7%8.6%
Revenue growth a year, past+5.1%over 5 years+17.2%over 5 years
EPS growth a year, past+8.3%over 5 years+21.8%over 5 years

Margins and returns on capital

ABTAZN
Margins and returns on capital
Gross margin56.9%81.9%
Operating margin13.8%23.4%
Net margin9.8%17.4%
ROIC6.3%14.8%
ROE9.1%21.0%

Balance sheet

ABTAZN
Balance sheet
Cash$4.3B$5.7B
Total debt$31.2B$26.5B
Net debt / EBITDA3.31.1
Interest cover6.7×8.1×

Dividends and buybacks

ABTAZN
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52$3.13
Dividend growth a year, past+10.4%over 5 years+2.3%over 5 years
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or AZN

Didn't find what you were looking for?

Ask us
How did ABT and AZN stock do over the last 10 years?

Since November 18, 2016, ABT's price moved +162.8% and AZN's +236.0%. With dividends: ABT +217.1% (+12.2% a year), AZN +341.4% (+16.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or AZN?

The dividend yield at today's price is 2.41% for Abbott Laboratories and none for AstraZeneca. Over the last twelve months they paid $2.52 and $3.13 per share.

Which has the higher profit margins, Abbott Laboratories or AstraZeneca?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 17.4% for AstraZeneca, and the operating margin 13.8% and 23.4%. Revenue was $48.2B and $58.7B.

Which is the better investment, Abbott Laboratories or AstraZeneca?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.